Results 51 to 60 of about 12,338 (219)

Pneumonitis associated with bortezomib in a patient with multiple myeloma [PDF]

, 2023
Introduction Bortezomib, which is widely used in the treatment of multiple myeloma (MM), is a proteasome inhibitor and acts by inducing apoptosis. Bortezomib has many side effects, mainly hematological, neurological, and gastrointestinal.
Kars, Taha Ulutan, Ceneli, Ozcan, Yaskiran, Osman   +2 more
core   +1 more source

Bortezomib-Induced Complete Heart Block and Myocardial Scar: The Potential Role of Cardiac Biomarkers in Monitoring Cardiotoxicity

Case Reports in Cardiology, 2016
Bortezomib is a proteasome inhibitor used to treat multiple myeloma and mantle cell lymphoma. Traditionally, bortezomib was thought to have little cardiovascular toxicity; however, there is increasing evidence that bortezomib can lead to cardiac ...
Sachin Diwadkar, Aarti A. Patel, Michael G. Fradley   +2 more
doaj   +1 more source

Homoharringtonine interacts synergistically with bortezomib in NHL cells through MCL-1 and NOXA-dependent mechanisms

BMC Cancer, 2018
Background Interactions between the protein synthesis inhibitor homoharringtonine (HHT) and the proteasome inhibitor bortezomib were investigated in DLBCL and mantle cell lymphoma cells (MCL).
Tri Nguyen, Rebecca Parker, Yu Zhang, Elisa Hawkins, Maciej Kmieciak, William Craun, Steven Grant   +6 more
doaj   +1 more source

Bortezomib is cytotoxic to the human growth plate and permanently impairs bone growth in young mice. [PDF]

PLoS ONE, 2012
Bortezomib, a novel proteasome inhibitor approved for the treatment of cancer in adults, has recently been introduced in pediatric clinical trials. Any tissue-specific side effects on bone development have to our knowledge not yet been explored.
Emma Eriksson, Farasat Zaman, Dionisios Chrysis, Henrik Wehtje, Terhi J Heino, Lars Sävendahl   +5 more
doaj   +1 more source

RNF138‐Mediated Ubiquitination and Degradation of NS5 Restricts Tick‐Borne Encephalitis Virus Infection

Advanced Science, EarlyView.
Host‐specific compatibility between RNF138‐like proteins and flavivirus NS5 determines NS5 stability. Mammalian RNF138 but not arthropod homologs recognizes and induces conserved NS5/RdRp K48‐linked ubiquitination and proteasomal degradation, thereby restricting viral replication. Ectopic RNF138 in mice attenuates TBEV‐induced pathogenesis. (Created in
Jialiang Sun, Weijing Yang, Hao Zhou, Shuai Li, Xin Jiang, Jianyang Gu, Wenyan Zhang   +6 more
wiley   +1 more source

The effect of the proteasome inhibitor bortezomib on acute myeloid leukemia cells and drug resistance associated with the CD34+ immature phenotype

Haematologica, 2008
Background Proteasome inhibition represents a promising novel anticancer therapy, and bortezomib is a highly selective reversible inhibitor of the proteasome complex.
Enrique Colado, Stela Álvarez-Fernández, Patricia Maiso, Jesús Martín-Sánchez, Maria Belén Vidriales, Mercedes Garayoa, Enrique M. Ocio, Juan Carlos Montero, Atanasio Pandiella, Jesús F. San Miguel   +9 more
doaj   +1 more source

Determinants of Long‐Term Benefit From High Dose Melphalan With Autologous Stem Cell Transplant in AL Amyloidosis

American Journal of Hematology, EarlyView.
ABSTRACT High dose melphalan (HDM) with autologous stem cell transplant is an established treatment for systemic light chain amyloidosis, but its incremental benefit in the era of effective standard intensity therapy is unknown. We retrospectively analyzed 475 transplant‐eligible patients who completed standard intensity treatment with or without HDM ...
Maximilian J. Steinhardt, Ute Hegenbart, Tamer Hellou, Sara Oubari, Murielle Roussel, Rahel Schwotzer, Francis Buadi, David Dingli, Moritz Binder, Taxiarchis Kourelis, Saurabh S. Zanwar, Max J. Rieger, Caroline Morbach, Vladimir Cejka, Bernhard Gerber, Stefan Störk, Hermann Einsele, Shaji Kumar, Morie Gertz, Alexander Carpinteiro, K. Martin Kortum, Eli Muchtar, Angela Dispenzieri, Stefan Schönland   +23 more
wiley   +1 more source

Multi-omics analysis identifies repurposing bortezomib in the treatment of kidney-, nervous system-, and hematological cancers

Scientific Reports
Repurposing of FDA-approved drugs is a quick and cost-effective alternative to de novo drug development. Here, we identify genes involved in bortezomib sensitivity, predict cancer types that may benefit from treatment with bortezomib, and evaluate the ...
Peter Larsson, Maxim Olsson, Sithumini Sarathchandra, Anna Fäldt Beding, Eva Forssell-Aronsson, Anikó Kovács, Per Karlsson, Khalil Helou, Toshima Z. Parris   +8 more
doaj   +1 more source

Chalazia development in multiple myeloma: a new complication associated with bortezomib therapy

Hematology Reports, 2015
Multiple myeloma (MM) is a neoplasm of plasma cells within the bone marrow. A major impact on improving survival in MM has been the use of the boronic acid-derived proteasome inhibitor bortezomib, a first-in-class selective inhibitor of the 26S ...
Charles Yun, Nikhil Mukhi, Valerie Kremer, Roman Shinder, Vaibhav Verma, Olcay Batuman   +5 more
doaj   +1 more source

Higher proteotoxic stress rather than mitochondrial damage is involved in higher neurotoxicity of bortezomib compared to carfilzomib

Redox Biology, 2020
Proteasome inhibitors have great success for their therapeutic potential against hematologic malignancies. First generation proteasome inhibitor bortezomib induced peripheral neuropathy is considered as a limiting factor in chemotherapy and its second ...
Ayse Tarbin Jannuzzi, Sema Arslan, Ayse Mine Yilmaz, Gulce Sari, Hande Beklen, Lucía Méndez, Maria Fedorova, Kazim Yalcin Arga, Betul Karademir Yilmaz, Buket Alpertunga   +9 more
doaj   +1 more source